Gastrointestinal stromal tumor and sarcoma research
Deciphera Pharmaceuticals Inc. focuses on advanced gastrointestinal stromal tumor (GIST), including patients with prior imatinib treatment, and related malignant solid tumors. Its clinical research also extends to metastatic solid tumor settings and broader advanced tumor populations.
- Advanced gastrointestinal stromal tumor
- Metastatic solid tumor
- Malignant solid tumors
- Advanced solid tumor
The sponsor’s portfolio includes studies in KIT-mutant disease and other solid tumor contexts where targeted treatment options remain limited.
Tenosynovial giant cell tumor and advanced tumor care
Another major area of interest is tenosynovial giant cell tumor (TGCT), with trials addressing patients with symptomatic disease and those with advanced tumors requiring specialized oncologic management. This includes research centered on tumor control and disease-specific response assessment.
- Tenosynovial giant cell tumor
- TGCT
- Advanced tumors
- Patients with advanced tumors
These studies reflect a strong therapeutic interest in rare soft tissue tumor biology and treatment options for patients with limited alternatives.
MAPK pathway-driven solid tumors
Deciphera also investigates solid tumors driven by the MAPK pathway, including molecularly defined cancers such as non-small cell lung cancer and other advanced malignancies with pathway activation. The research emphasis is on tumors characterized by specific signaling abnormalities.
- MAPK pathway-driven solid tumors
- Non-small cell lung cancer
- Advanced solid tumor
- Melanoma
Its clinical activity includes both monotherapy and combination settings across molecularly targeted oncology indications.
Primary central nervous system lymphoma and B-cell malignancy research
The sponsor supports research in relapsed/refractory primary central nervous system lymphoma (PCNSL), a difficult-to-treat lymphoma involving the central nervous system. This area links neuro-oncology with hematologic cancer care.
- Relapsed/refractory primary central nervous system lymphoma
- Primary CNS lymphoma
- Lymphoma
- B-cell malignancy
These trials address treatment options for patients with recurrent disease and limited therapeutic pathways.
Targeted oncology across advanced malignancies
Across its trial portfolio, Deciphera concentrates on advanced malignancies that span solid tumors, rare tumor types, and selected hematologic cancers. The research landscape includes disease areas where targeted therapy and precision oncology are central therapeutic interests.
- Advanced malignancies
- Solid tumors
- Precision oncology
- Targeted therapy
Its funded studies span multiple tumor types in oncology, with a clear focus on disease-specific treatment development.
